Effect of supplementary feeding on the side effects associated with cancer therapy with Oxaliplatin or Irinotecan

Effect of supplementary feeding on the side effects associated with cancer therapy with Oxaliplatin or Irinotecan - Oxa-Iri-EVENTS

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00008547

Enrollment

750

Registered

2015-05-27

Start date

2015-06-16

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C18 C18.1 C18.2 C18.3 C18.4 C18.5 C18.6 C18.7 C18.8 C18.9 C19 C20

Interventions

Group 1: In this single-arm medicament study the role of nutrition should be studied in the side effects of Oxaliplatin / Irinotecan with a particular in a relatively large group of patients. Riboxati

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patient: - adults capable to consent (> 18 years)

Exclusion criteria

Exclusion criteria: Patients under 18 years , pregnant women , patients uncapable to consent

Design outcomes

Primary

Measure	Time frame
The influence of the nutritional status of patients on the severity of the side effects of treatment with oxaliplatin or irinotecan (Riboxatin® or Riboirino®).	—

Secondary

Measure	Time frame
Influence of other dietary supplements on the side effects of treatment with oxaliplatin or irinotecan. (Riboxatin® or Riboirino®)	—

Countries

Germany

Contacts

Public ContactHayssam Zakaria

NewConceptOncology GmbH

info@n-c-o.de0511 76355 123

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026